Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Investment analysts at B. Riley cut their Q2 2019 EPS estimates for Karyopharm Therapeutics in a research report issued on Wednesday, July 10th. B. Riley analyst H. Polishetty now forecasts that the company will post earnings of ($1.15) per share for the quarter, down from their prior estimate of ($0.97). B. Riley also issued estimates for Karyopharm Therapeutics’ Q3 2019 earnings at ($1.24) EPS, Q4 2019 earnings at ($1.34) EPS, FY2019 earnings at ($4.79) EPS, FY2020 earnings at ($4.80) EPS, FY2021 earnings at ($3.56) EPS, FY2022 earnings at ($1.93) EPS and FY2023 earnings at $0.00 EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%. The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.75 million.

Several other research analysts have also commented on the company. Robert W. Baird reiterated an “outperform” rating and issued a $25.00 price target (up previously from $15.00) on shares of Karyopharm Therapeutics in a research report on Friday, July 5th. Zacks Investment Research upgraded Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Saturday. Wedbush set a $11.00 price target on Sangamo Therapeutics and gave the stock a “hold” rating in a research report on Monday, July 8th. ValuEngine upgraded Zillow Group from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $48.00 price target (down previously from $52.00) on shares of CELYAD SA/ADR in a research report on Friday, July 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $17.41.

Shares of KPTI stock opened at $8.03 on Friday. Karyopharm Therapeutics has a 12-month low of $3.92 and a 12-month high of $21.71. The company has a quick ratio of 6.19, a current ratio of 6.19 and a debt-to-equity ratio of 0.98. The stock has a 50-day moving average price of $6.37. The company has a market capitalization of $463.18 million, a PE ratio of -2.56 and a beta of 2.43.

Several large investors have recently made changes to their positions in the business. Ridgeback Capital Investments L.P. purchased a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $36,967,000. FMR LLC boosted its position in shares of Karyopharm Therapeutics by 51.5% during the fourth quarter. FMR LLC now owns 1,875,140 shares of the company’s stock valued at $17,570,000 after buying an additional 637,357 shares during the period. Candriam Luxembourg S.C.A. boosted its position in shares of Karyopharm Therapeutics by 4.1% during the first quarter. Candriam Luxembourg S.C.A. now owns 1,866,778 shares of the company’s stock valued at $10,902,000 after buying an additional 74,234 shares during the period. Emerald Advisers LLC boosted its position in shares of Karyopharm Therapeutics by 3.5% during the first quarter. Emerald Advisers LLC now owns 1,508,094 shares of the company’s stock valued at $8,807,000 after buying an additional 51,621 shares during the period. Finally, Frontier Capital Management Co. LLC boosted its position in shares of Karyopharm Therapeutics by 311.9% during the first quarter. Frontier Capital Management Co. LLC now owns 683,363 shares of the company’s stock valued at $3,991,000 after buying an additional 517,464 shares during the period. Institutional investors and hedge funds own 84.20% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Further Reading: 52-Week High/Low Prices For Stock Selection

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.